This trial is active, not recruiting.

Conditions myocardial infarction, coronary artery disease
Treatment abciximab
Sponsor University of Melbourne
Start date February 2012
End date June 2014
Trial size 40 participants
Trial identifier NCT02105870, SVH 001


Microvascular dysfunction is a key determinant of pathogenesis and outcome in patients suffering an acute myocardial infarction.

The investigators hypothesise that treatment with intracoronary abciximab, a potent anti platelet agent, at the time of coronary stent insertion, will improve microvascular function.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Intracoronary abciximab (Reopro)
abciximab Reopro
This drug will be administered intracoronary before percutaneous coronary intervention.
(Placebo Comparator)
Intracoronary Reopro

Primary Outcomes

Index of Microvascular Resistance
time frame: within 3 hours

Secondary Outcomes

Incidence of periprocedural myocardial infarction
time frame: within 24 hours

Eligibility Criteria

Male or female participants from 18 years up to 85 years old.

Inclusion Criteria: - Patient with acute coronary syndromes Exclusion Criteria: - Patient with untreated malignancy, disseminated malignancy, active inflammatory diseases, active infectious diseases patients unable to give informed consent Patients with STEMI

Additional Information

Official title A Randomized Control Trial of Intracoronary Reopro to Improve Coronary Microvascular Function
Principal investigator Andrew Wilson, MD PhD
Description The index of microcirculatory resistance (IMR), an invasive measure of coronary microvascular function, correlates with clinical outcomes in patients with stable angina and ST elevation myocardial infarction. The glycoprotein IIb/IIIa receptor inhibitor, abciximab, improves coronary microvascular function and reduces major cardiac adverse events in patients with acute coronary syndromes. This study will investigate whether an intracoronary bolus of abciximab in patients with non-ST elevation myocardial infarction decreases IMR and improves microvascular function.
Trial information was received from ClinicalTrials.gov and was last updated in April 2014.
Information provided to ClinicalTrials.gov by University of Melbourne.